Skip to main content
. 2022 Jul 15;84(4):375–383. doi: 10.1055/s-0042-1751291

Table 1. Patient history, demographics, and imaging characteristics in early, middle, and late cohorts.

Epoch Total
N  = 66
2005–2010 ( N  = 20) 2011–2015
( N  = 23)
2016–2020 ( N  = 23) Significance
Age (median, interquartile range) 39 (IQR 30.5–56.3) 46.5 (30–56.8) 39 (28–64.2) 39 (32–67) 0.435
Sex Female 25 (37.9%) 8 (40%) 10 (43.5%) 7 (30.4%) 0.642
Presenting symptom Vision loss 60 (91%) 20 (100%) 23 (100%) 17 (73.9%) 0.002
Headache 31 (47%) 8 (40%) 13 (56.5%) 10 (43.5%) 0.510
Endocrinopathy 18 (27%) 4 (20%) 9 (39.1%) 5 (21.7%) 0.284
Weight gain 7 (11%) 0 (0%) 3 (13%) 4 (17.4%) 0.163
Fatigue 10 (15%) 1 (5%) 5 (21.7%) 4 (17.4%) 0.291
Memory/cognitive 6 (9%) 2 (10%) 0 (0) 4 (17.4%) 0.120
Prior surgery Transcranial 9 (14%) 5 (25%) 3 (13%) 1 (4.3%) 0.243
Transsphenoidal 5 (7.6%) 2 (10%) 2 (8.7%) 1 (4.3%) 0.345
Prior radiotherapy 4 (6.0%) 3 (15%) 1 (4.3%) 0 (0) 0.139
Prior intracystic therapy Ommaya reservoir 1 (1.5%) 0 (0) 1 (1.5%) 0 (0)
Intracystic therapy 0 (0) 0 (0) 0 (0)
Max tumor diameter, cm (median, interquartile range) 2.91 (2.1–3.5) 2.9 (2.3–4.2) 3.0 (2.1–3.3) 2.7 (2.1–3.2) 0.415
Tumor consistency a Solid 6 (9.0%) 3 (15%) 2 (8.7%) 1 (4.3%) 0.785
Cystic 13 (20%) 4 (20%) 5 (21.7%) 4 (17.4%)
Solid and cystic 47 (71%) 13 (65%) 16 (69.6%) 18 (82.6%)
Hypothalamic involvement b 55 (83.3%) 19 (95%) 19 (82.6%) 17 (73.9%) 0.179
Pathology Adamantinomatous 47 (71.2%) 14 (70%) 15 (65.2%) 18 (78.3%) 0.501
Papillary 17 (25.8%) 5 (25%) 8 (34.8%) 5 (21.7%)
a

Tumor was graded as primarily cystic or solid if >90% of the tumor was cystic or solid, respectively.

b

Hypothalamic involvement was present if the tumor displaced or invaded the medial or inferior hypothalamus on at least one side. Bold values indicate significant level less than 0.05.